Product
High-Dose Quadrivalent Influenza Vaccine
Aliases
Efluelda®, QIV-HD
5 clinical trials
3 indications
Indication
Influenza ImmunizationIndication
InfluenzaIndication
Healthy Control ParticipantsClinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High Dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2023/24Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High-dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2022/23.Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2021/22.Status: Completed, Estimated PCD: 2021-12-02
Clinical trial
Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in JapanStatus: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older AdultsStatus: Recruiting, Estimated PCD: 2025-05-31